DTIL
NASDAQ HealthcarePrecision BioSciences, Inc. - Common Stock
Biotechnology
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
�� 市场数据
| 价格 | $7.88 |
|---|---|
| 成交量 | 251,655 |
| 市值 | 203.33M |
| 贝塔系数 | 1.090 |
| RSI（14日） | 74.1 超买 |
| 200日均线 | $5.14 |
| 50日均线 | $5.37 |
| 52周最高 | $8.82 |
| 52周最低 | $3.53 |
| Forward P/E | -2.41 |
| Price / Book | 2.06 |
🎯 投资策略评分
DTIL 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (54/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🐋 Institutional Whale (4/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 DTIL in your text
粘贴任何文章、记录或帖子 — 工具将提取 DTIL 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.